Zura Bio Limited (NASDAQ:ZURA) is one of the 10 High Growth Stocks Insiders Are Buying. On July 8, 2026, William Blair initiated coverage of Zura Bio Limited (NASDAQ:ZURA) with an Outperform rating. The firm sees potential for the dual mechanism of action of tibulizumab to drive “differentiated efficacy” in two ongoing Phase 2 studies in […]

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Viewing insider transactions for Zura Bio Limited's ( NASDAQ:ZURA ) over the last year, we see that insiders were net...

This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs.

RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials.

This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology.

Zura Bio (NASDAQ:ZURA) outlined its near-term clinical milestones and strategy at Guggenheim Securities’ Emerging Outlook Biotech Summit 2026, emphasizing upcoming Phase 2 readouts for its lead bispecific antibody, tibulizumab, in autoimmune and inflammatory diseases. New CEO highlights shift towar

As the United States market experiences fluctuations, with technology shares weighing on major indices like the Nasdaq, investors are closely monitoring economic indicators and Federal Reserve actions. In this context, penny stocks—often seen as smaller or newer companies—remain a compelling area of interest due to their potential for growth when backed by strong financials. Despite being an outdated term, these stocks can offer unique opportunities for investors seeking to uncover hidden...

With strong three-month performance and significant upside potential, Zura Bio Limited (NASDAQ:ZURA) secures a spot on our list of the 12 hot penny stocks to invest in right now. On November 13, 2025, Guggenheim reiterated its “Buy” rating on Zura Bio Limited (NASDAQ:ZURA) with a $15 price target. The reaffirmed outlook came as Zura Bio […]

As U.S. stock indexes hit record highs amid optimism over trade discussions between the U.S. and China, investors are increasingly looking for opportunities beyond the major indices. Penny stocks, often associated with smaller or newer companies, remain a relevant investment area despite their somewhat outdated label. These stocks can offer significant growth potential when backed by strong financials, and we will explore several that stand out as promising candidates for those seeking hidden...